Tyche Wealth Partners LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Tyche Wealth Partners LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,086 shares of the company’s stock, valued at approximately $1,799,000.

Other hedge funds have also recently modified their holdings of the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the third quarter valued at about $27,000. Retirement Group LLC increased its holdings in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares in the last quarter. Cornerstone Planning Group LLC acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $33,000. Finally, Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the third quarter valued at about $35,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

Shares of NYSE:LLY traded down $4.21 during midday trading on Tuesday, reaching $746.56. 2,569,130 shares of the company’s stock were exchanged, compared to its average volume of 3,085,273. The firm’s 50 day simple moving average is $762.68 and its two-hundred day simple moving average is $655.54. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a market cap of $709.35 billion, a price-to-earnings ratio of 128.34, a P/E/G ratio of 1.65 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the company earned $2.09 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 12.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Barclays increased their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Truist Financial reiterated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.